

EQUITY RESEARCH

STAR7
RESULTS REVIEW
Press release

BUY

TP 12.9€ (vs 12.2€) Up/Downside: 37%

STAR7 Is Pursuing Growth

The 2022 Value of Production stands at €85m (vs. €82.9 expected), EBITDA beating expectations at €15.1m and net debt of €35.6m (vs €31.9m YoY), for a net debt/EBITDA ratio down to 2.4x (vs. 3.9x YoY). The M&A potential is back.

Star7 has released a solid consolidated balance sheet despite the market environment. Revenue amounted to €83.3m (+41% vs. €59m YoY), EBITDA €15.1m (+82.9% vs. €8.3m YoY), EBITDA margin 18.2% (vs. 14% YoY), net income of €3.1m (vs. €2.5m) and net debt of €35.1m (vs. €31.9m YoY).

Growth was driven partly by M&A (for around €18m, mainly LocalEyes and Geo Group) and partly by organic growth (for additional €6.2m). Italy's impact on revenue decreased to 55.8% (vs. 58.3% YoY) in favour of US sales for 28.2% (vs. 27.9%) and Brazilian sales for 8.7% (vs. 6.5%).

In terms of BU mix on revenue, there was substantial organic growth for the Printing division (particularly in Brazil and Italy), which generated revenue of ϵ 14.8m (vs. ϵ 10m YoY); followed by Global Content at ϵ 38.5m (vs. ϵ 20m YoY, with M&A transactions contributing ϵ 17.7m to growth); and finally the Engineering division for ϵ 29.9m (vs. ϵ 28.9m YoY).

Over 300 engineers have been integrated into STAR7, following the lease of the CAAR and STI business, which we estimate will result in around €15m of additional revenue and a 2023 EBITDA margin contribution between 5% and 10%. For this reason, we have raised our 2023 EBITDA estimate to €18m (vs. €17.1m previously), while incorporating in the model an extraordinary impact of reorganisation and consolidation costs between the two companies. In addition, we have cautiously increased the cost of debt, although much of this is related to the issuance of two miniBonds with a total value of €25m with a fixed rate.

The M&A focus is currently on the Product Knowledge division, which is targeting an Italian packaging company and a US agricultural company. The Global Content division aims to strengthen its presence in the fashion and pharmaceutical sectors. STAR7 is also moving into generative AI.

Due to the quality of the acquired clients, the large number of specialized engineers integrated in STAR7 and management's renewed vision, we are reiterating our Buy rating and upgrading our TP to €12.9 (vs €12.2 previously).

Key data

Price (€)	9.4
Industry	Corporate Services
Ticker	STAR7-IT
Shares Out (m)	9.000
Market Cap (m €)	85.0

Ownership (%)

Dante Srl	39.2
Star Ag	31.4
Kairos Partners SGR SpA	6.1
Free float	23.3

EPS (€)	12/23e	12/24e	12/25e
Estimates	0.71	0.80	0.96
Change vs previous estimates (%)	9.85	10.10	8.86

Performance (%)	1D	1M	YTD
Price Perf	-1.0	2.2	11.1
Rel FTSE Italy	-1.8	6.5	1.2



TP ICAP Midcap Estimates	12/22	12/23e	12/24e	12/25e
Sales (m €)	85.0	107.3	116.4	125.1
Current Op Inc (m ϵ)	7.5	9.9	11.0	12.7
Current op. Margin (%)	8.8	9.3	9.4	10.2
EPS (€)	0.40	0.71	0.80	0.96
DPS (€)	0.00	0.00	0.00	0.00
Yield (%)	0.0	0.0	0.0	0.0
FCF (m €)	-1.6	5.1	9.6	11.8

12/25e
0.8
4.2
7.5
9.8
11.8

Consensus FactSet - Analysts:2	12/23e	12/24e	12/25e
Sales	105.4	114.5	0.0
EBIT	9.0	10.0	0.0
Net income	4.9	5.6	0.0





FINANCIAL DATA

Sales	Income Statement	12/20	12/21	12/22	12/23e	12/24e	12/25e
Changes (%) 17,0 34,6 41,6 26,3 8,4 1015 1704 19,0 Cross profict 41,8 55,3 80,4 1015 1704 19,0 Sed TSAles 3,8 93,7 1946 14,6 9,0 202-24 Kof Sales 6.0 6.8 8.8 9,3 104 12,2 Sol Sales 6.0 6.8 8.8 9,3 104 10,2 ERIT 2.5 4.0 73 9,8 10.8 11,5 Non-recurring ferms 0.2 0.4 73 9,8 10.8 11,5 Net financial result 0.3 0.6 2.3 2.3 2.4 2.0 12,2 Net financial result 0.2 2.4 35.7 37.9 10.8 12,2 Net financial result 0.2 2.4 35.3 35.9 30.9 10.9 12.9 Text from figures 0.2 2.4 2.4 35.2 35.3 <t< td=""><td></td><td>44.6</td><td>60.0</td><td>85.0</td><td>107.3</td><td>116.4</td><td>125.1</td></t<>		44.6	60.0	85.0	107.3	116.4	125.1
Gross profife 41.8 56.3 80.4 101.5 10.4 10.90 % of Sales 93.8 93.7 94.8 94.6 94.8 153. % of Sales 9.8 33.8 17.8 10.7 17.3<							
96 of Sales 93,8 b 93,7 b 94,6 b 94,8 b 93,8 b 15,4 b 16,0 b 20,2 b 22,1 b 22,2 b 22	•						
EBITION 4.4 8.3 15.1 18.0 20.2 22.4 9s of Sales 9.3 13.8 17.8 16.9 17.3 17.9 17.0 12.2 9s of Sales 6.0 6.8 8.8 9.3 1.0 10.2 Sof Sales 6.0 6.8 8.8 9.3 1.0 10.2 Northerouring items 0.2 4.0 9.3 2.5 1.0 2.0 Not findical result 0.3 0.6 3.3 3.3 3.3 3.3 Not profit, group share 1.5 2.2 3.3 5.4 6.1 7.7 Firs 1.0 2.0 1.2 1.2 1.2 1.2 Scodwill 4.8 3.5 3.19 3.41 4.3 2.5 Goodwill 4.8 3.5 3.19 3.41 4.9 2.2 Goodwill 4.8 3.5 3.1 3.4 4.9 4.9 Eight of Use 0.0	*						
Of Sales 9.8 1.0.8 17.8 16.7 17.3 17.0 Current operating profit 2.7 4.4 7.8 9.9 11.0 12.0 Sof of Sales 6.0 6.8 8.8 8.0 10.0 10.2 Sor recurring items 0.2 0.1 0.1 0.0 10.2 12.2 EBIT 2.0 4.0 7.3 9.8 10.8 10.2 12.2 EMET financial result 0.3 0.6 2.0 2.0 2.2 2.2 2.2 Increed Tax 0.4 0.4 0.9 2.0 2.2							
Current operating profit 1.0 4.1 7.5 9.9 1.0 1.7 % of Sales 6.0 6.0 6.0 8.8 9.3 9.4 10.2 ERIT 2.0 4.0 0.1 0.1 0.1 12.5 Net financial result 0.3 4.0 0.2 2.3 2.3 2.3 Income Tax 0.4 0.0 2.0 2.1 2.2 2.2 Tax rate (%) 1.0 1.0 1.6 3.8 3.7 2.79 2.79 Net profit, group share 1.1 2.0 4.0 3.0 4.0 0.7 2.0 2.79 Pinancial Statement 1.7 1.2 1							
When Fallers 6.6 6.8 8.8 9.3 9.4 10.2 Non-recurring items 0.2 0.1 0.3 0.1 0.2 0.2 EBIT 2.5 4.0 7.3 9.8 10.3 2.3 2.3 2.3 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.24 2.20 1.24 1.24 2.20 1.24 1.24 2.20 1.24							
Non-recurring items α.σ. σ.σ. σ.σ. σ.σ.σ. σ.σ.σ. σ.σ.σ. σ.σ.σ. σ.							
Part							
Net financial result							
Income Tax 0.4 0.9 2.0 2.1 2.9 2.79							
Part							
Net profit, group share 1.5 2.2 3.1 5.4 6.1 7.4 EFS na 0.29 0.40 0.71 0.80 0.96 Financial Statement 12/20 12/21 12/22 12/32 12/24 12/23 12/24 12/25 12/25 12/24 12/25 12/24 12/25 12/24 12/25 12/24 12/25 <							
Prinancial Statement							
Financial Statement 12/20 12/21 12/220 12/240 12/240 Goodwill 4.8 35.5 31.9 34.1 29.2 24.7 Tangible and intangible assets 8.9 12.0 14.1 15.8 15.8 14.8 Right of Use 0.0							
Coodwill	110	iia	0.29	0.40	0./1	0.00	0.90
Tangible and intangible assets 8.89 12.0 14.1 15.8 15.8 14.8 18.8 18.8 14.8 18.8 16.1 19.5 10.0 10	Financial Statement	12/20	12/21	12/22	12/23e	12/24e	12/25e
Right of Use 0.0 0.0 0.0 0.0 0.0 Financial assets 0.5 0.3 0.8 0.8 0.8 0.8 Working capital 17.8 15.3 25.0 2.8.8 30.2 31.3 Other Assets 0.0 0.0 0.0 0.0 0.0 0.0 AssetS 32.0 63.1 71.8 79.4 76.0 71.5 Shareholders equity group 10.3 24.6 29.2 34.5 40.7 48.1 Minorities 0.7 0.9 0.0 0.0 0.0 0.0 LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 Net debt 14.5 27.1 30.7 31.6 22.0 10.2 Other liabilities 1.8 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 <td>Goodwill</td> <td>4.8</td> <td>35.5</td> <td>31.9</td> <td>34.1</td> <td>29.2</td> <td>24.7</td>	Goodwill	4.8	35.5	31.9	34.1	29.2	24.7
Financial assets 0.5 0.3 0.8 0.8 0.8 0.8 Working capital 17.8 15.3 25.0 28.8 30.2 31.3 Other Assets 0.0 0.0 0.0 0.0 0.0 0.0 Assets 32.0 63.1 71.8 79.4 75.0 75.5 Shareholders equity group 10.3 24.6 29.2 34.5 40.7 48.1 Minorities 0.7 0.9 0.0 0.0 0.0 0.0 LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 8.4 Net debt 14.5 27.1 30.7 31.6 22.0 10.0 Other liabilities 1.8 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.0 1.0 1.0 1.0 1.0 1.0 2.0 1.0 2.0 1.0 2.0 1.0 2.0 1.0	Tangible and intangible assets	8.9	12.0	14.1	15.8	15.8	14.8
Working capital 17.8 15.3 25.0 28.8 30.2 31.3 Other Assets 0.0 0.0 0.0 0.0 0.0 0.0 Assets 32.0 63.1 71.8 79.4 76.0 71.5 Shareholders equity group 10.3 24.6 29.2 34.5 40.7 48.0 Minorities 0.7 0.9 0.0 0.0 0.0 0.0 0.0 LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 8.4 Net debt 14.5 27.1 30.7 31.6 22.0 10.2 Other liabilities 1.8 4.9<	Right of Use	0.0	0.0	0.0	0.0	0.0	0.0
Other Assets 32.0 63.1 71.8 79.4 76.0 71.5 Shareholders equity group 10.3 24.6 29.2 34.5 40.7 48.1 Minorities 0.7 0.9 0.0 0.0 0.0 0.0 LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 8.4 Net debt 14.5 22.1 30.7 31.6 22.0 10.2 Other liabilities 1.8 4.9	Financial assets	0.5	0.3	0.8	0.8	0.8	0.8
Assets 32.0 63.1 71.8 79.4 76.0 71.8 Shareholders equity group 10.3 24.6 29.2 34.5 40.7 48.1 Minorities 0.7 0.9 0.0 0.0 0.0 0.0 LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 8.4 Net debt 14.5 27.1 30.7 31.6 22.0 10.2 Other liabilities 1.8 4.9 4.0 4.0 <td>Working capital</td> <td>17.8</td> <td>15.3</td> <td>25.0</td> <td>28.8</td> <td>30.2</td> <td>31.3</td>	Working capital	17.8	15.3	25.0	28.8	30.2	31.3
Shareholders equity group 10.3 24.6 29.2 34.5 40.7 48.1 Minorities 0.7 0.9 0.0 0.0 0.0 0.0 LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 8.4 Net debt 14.5 27.1 30.7 31.6 22.0 10.2 Other liabilities 1.8 4.9	Other Assets	0.0	0.0	0.0	0.0	0.0	0.0
Minorities 0.7 0.9 0.0 0.0 0.0 0.0 LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 8.4 Net debt 14.5 27.1 30.7 31.6 22.0 10.2 Other liabilities 1.8 4.9 <	Assets	32.0	63.1	71.8	79-4	76.0	71.5
LT & ST provisions and others 4.7 5.7 7.1 8.4 8.4 8.4 Net debt 145 27.1 30.7 31.6 22.0 10.2 Other liabilities 1.8 4.9 4.9 4.9 4.9 4.9 Liabilities 32.0 63.1 71.8 79.4 76.0 71.5 Net debt excl. IFRS 16 14.5 27.1 30.7 31.6 22.0 10.2 Gearing net 1.3 1.1 1.1 0.9 0.5 0.2 Leverage 3.3 3.3 2.0 1.8 1.1 0.5 Cash flow statement 12/20 12/21 12/22 12/23e 12/24e 12/24e 12/24e 12/24e 12/24	Shareholders equity group	10.3	24.6	29.2	34.5	40.7	48.1
Net debt 14,5 27,1 30,7 31,6 22,0 10.2 Other liabilities 1,8 4.9 7.6 7.15 7.0 7.15 7.0 7.15 7.0 7.1 1.0 0.0 0.2 1.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.	Minorities	0.7	0.9	0.0	0.0	0.0	0.0
Net debt 14,5 27,1 30,7 31,6 22,0 10.2 Other liabilities 1,8 4.9 4.0 10.2 10.2 10.2 10.2 10.2 10.2 10.2 10.2 10.2 12.2 12.3 12.4 12.2 12.3 12.4 12.2 12.3 12.4 12.2 12.3 11.1 11.0 10.0	LT & ST provisions and others	4.7	5.7	7.1	8.4	8.4	8.4
Liabilities 32.0 63.1 71.8 79.4 76.0 71.5 Net debt excl. IFRS 16 14.5 27.1 30.7 31.6 22.0 10.2 Gearing net 1.3 1.1 1.1 0.9 0.5 0.2 Leverage 3.3 3.3 2.0 1.8 1.1 0.5 Cash flow statement 12/20 12/21 12/22 12/3e 12/2e 12/2e CF after elimination of net borrowing costs and taxes 3.2 6.7 12.1 13.4 15.3 17.1 ΔWCR 2.2 2.2 9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 0.0 0.0 0.0 0.0 0.0	Net debt	14.5	27.1	30.7	31.6	22.0	10.2
Liabilities 32.0 63.1 71.8 79.4 76.0 71.5 Net debt excl. IFRS 16 14.5 27.1 30.7 31.6 22.0 10.2 Gearing net 1.3 1.1 1.1 0.9 0.5 0.2 Leverage 3.3 3.3 2.0 1.8 1.1 0.5 Cash flow statement 12/20 12/21 12/22 12/23e 12/24e 12/25e CF after elimination of net borrowing costs and taxes 3.2 6.7 12.1 13.4 15.3 17.1 AWCR 2.2 2.2 2.9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 0.0 0.0 0.0 0.0 Change i	Other liabilities	1.8	4.9	4.9	4.9	4.9	4.9
Net debt excl. IFRS 16 14-5 27-1 30-7 31-6 22-0 10-2 Gearing net 1.3 1.1 1.1 0.9 0.5 0.2 Leverage 3.3 3.3 2.0 1.8 1.1 0.5 Cash flow statement 12/20 12/21 12/22 12/29 12/24e 12/25e CF after elimination of net borrowing costs and taxes 3.2 6.7 12.1 13.4 15.3 17.1 ΔWCR 2.2 2.2 -9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0	Liabilities	32.0					
Gearing net 1.3 1.1 1.1 0.9 0.5 0.2 Leverage 3.3 3.3 2.0 1.8 1.1 0.5 Cash flow statement 12/20 12/21 12/22 12/28 12/24e 12/25e CF after elimination of net borrowing costs and taxes 3.2 6.7 12.1 13.4 15.3 17.1 ΔWCR 2.2 2.2 -9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Dividends paid 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Net debt excl. IFRS 16	14.5	27.1			22.0	
Leverage 3.3 3.3 2.0 1.8 1.1 0.5 Cash flow statement 12/20 12/21 12/22 12/23e 12/24e 12/25e CF after elimination of net borrowing costs and taxes 3.2 6.7 12.1 13.4 15.3 17.1 ΔWCR 2.2 2.2 -9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Other investments 0.0 0.0 0.0 0.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Equity Transaction 0.0 0.0 0.0 0.0 0.0 0.0	Gearing net					0.5	0.2
Cash flow statement 12/20 12/21 12/22 12/23e 12/24e 12/25e CF after elimination of net borrowing costs and taxes 3.2 6.7 12.1 13.4 15.3 17.1 ΔWCR 2.2 2.2 -9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Other investments 0.0 0.0 0.0 0.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Dividends paid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Repayment of leasing debt 0.0 0.0 0.0 0.0	ů		3.3	2.0			0.5
CF after elimination of net borrowing costs and taxes 3.2 6.7 12.1 13.4 15.3 17.1 ΔWCR 2.2 2.2 -9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 0.0 Other investments 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Other investments 1.8 33.1 -1.8 3.2 0.0 0.0 Other investments 1.8 1.8 1.8 1.8 3.2 0.0 0.0 Other investments 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8							
AWCR 2.2 2.2 -9.8 -3.8 -1.4 -1.1 Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Other investments 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Dividends paid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Repayment of leasing debt 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Equity Transaction 0.0 11.8 0.0 0.0 0.0 0.0 Others -0.2 0.0 0.1 0.0 0.0 0.0 Change in net cash over the year 1.8 16.5 -5.5 2.3 <t< td=""><td>Cash flow statement</td><td>12/20</td><td>12/21</td><td>12/22</td><td>12/23e</td><td>12/24e</td><td>12/25e</td></t<>	Cash flow statement	12/20	12/21	12/22	12/23e	12/24e	12/25e
Operating cash flow 5.5 8.9 2.2 9.7 14.0 16.0 Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Other investments 0.0 0.0 0.0 0.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Dividends paid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Repayment of leasing debt 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Equity Transaction 0.0 11.8 0.0 0.0 0.0 0.0 Others -0.2 0.0 0.1 0.0 0.0 0.0 Change in net cash over the year 1.8 16.5 -5.5 2.3 9.6 11.8 <td>CF after elimination of net borrowing costs and taxes</td> <td>3.2</td> <td>6.7</td> <td>12,1</td> <td>13.4</td> <td>15.3</td> <td>17.1</td>	CF after elimination of net borrowing costs and taxes	3.2	6.7	12,1	13.4	15.3	17.1
Net capex -5.2 -6.0 -3.9 -4.5 -4.4 -4.2 FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Other investments 0.0 0.0 0.0 0.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Dividends paid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Repayment of leasing debt 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Equity Transaction 0.0 11.8 0.0 0.0 0.0 0.0 Others -0.2 0.0 0.1 0.0 0.0 0.0 Change in net cash over the year 1.8 16.5 -5.5 2.3 9.6 11.8	ΔWCR	2.2	2.2	-9.8	-3.8	-1.4	-1,1
FCF 0.3 3.0 -1.6 5.1 9.6 11.8 Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Other investments 0.0 0.0 0.0 0.0 0.0 0.0 Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Dividends paid 0.0 0.0 0.0 0.0 0.0 0.0 Repayment of leasing debt 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Equity Transaction 0.0 11.8 0.0 0.0 0.0 0.0 Others -0.2 0.0 0.1 0.0 0.0 0.0 Change in net cash over the year 1.8 16.5 -5.5 2.3 9.6 11.8 ROA (%) 5.3% 3.9% 4.3% 6.8% 8.1% 10.3%	Operating cash flow	5.5	8.9	2.2	9.7	14.0	16.0
Acquisitions/Disposals of subsidiaries 0.0 -31.6 -2.2 -6.0 0.0 0.0 Other investments 0.0 </td <td>Net capex</td> <td>-5.2</td> <td>-6.0</td> <td>-3.9</td> <td>-4.5</td> <td>-4.4</td> <td>-4.2</td>	Net capex	-5.2	-6.0	-3.9	-4.5	-4.4	-4.2
Other investments 0.0 <td>FCF</td> <td>0.3</td> <td>3.0</td> <td>-1.6</td> <td>5.1</td> <td>9.6</td> <td>11.8</td>	FCF	0.3	3.0	-1.6	5.1	9.6	11.8
Change in borrowings 1.8 33.1 -1.8 3.2 0.0 0.0 Dividends paid 0.0	Acquisitions/Disposals of subsidiaries	0.0	-31.6	-2.2	-6.0	0.0	0.0
Dividends paid 0.0	Other investments	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of leasing debt 0.0 <t< td=""><td>Change in borrowings</td><td>1.8</td><td>33.1</td><td>-1.8</td><td>3.2</td><td>0.0</td><td>0.0</td></t<>	Change in borrowings	1.8	33.1	-1.8	3.2	0.0	0.0
Equity Transaction 0.0 11.8 0.0 0.0 0.0 0.0 Others -0.2 0.0 0.1 0.0 0.0 0.0 Change in net cash over the year 1.8 16.5 -5.5 2.3 9.6 11.8 ROA (%) 5.3% 3.9% 4.3% 6.8% 8.1% 10.3%	Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others -0.2 0.0 0.1 0.0 0.0 0.0 Change in net cash over the year 1.8 16.5 -5.5 2.3 9.6 11.8 ROA (%) 5.3% 3.9% 4.3% 6.8% 8.1% 10.3%	Repayment of leasing debt	0.0	0.0	0.0	0.0	0.0	0.0
Change in net cash over the year 1.8 16.5 -5.5 2.3 9.6 11.8 ROA (%) 5.3% 3.9% 4.3% 6.8% 8.1% 10.3%	Equity Transaction	0.0	11.8	0.0	0.0	0.0	0.0
ROA (%) 5.3% 3.9% 4.3% 6.8% 8.1% 10.3%	Others	-0.2	0.0	0.1	0.0	0.0	0.0
• •	Change in net cash over the year	1.8	16.5	-5.5	2.3	9.6	11.8
• •							
ROE (%) 16.3% 10.0% 10.6% 15.6% 15.1% 15.4%	ROA (%)	5.3%	3.9%	4.3%	6.8%	8.1%	10.3%
	ROE (%)	16.3%	10.0%	10.6%	15.6%	15.1%	15.4%



DISCLAIMER

Analyst certifications

This research report (the "Report") has been approved by Midcap, a business division of TP ICAP (Europe) SA ("Midcap"), an Investment Services Provider authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution ("ACPR"). By issuing this Report, each Midcap analyst and associate whose name appears within this Report hereby certifies that (i) the recommendations and opinions expressed in the Report accurately reflect the research analyst's and associate's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's or associate's compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst or associate in the Report.

Methodology

This Report may mention evaluation methods defined as follows:

- 1. DCF method: discounting of future cash flows generated by the company's operations. Cash flows are determined by the analyst's financial forecasts and models. The discount rate used corresponds to the weighted average cost of capital, which is defined as the weighted average cost of the company's debt and the theoretical cost of its equity as estimated by the analyst.
- 2. Comparable method: application of market valuation multiples or those observed in recent transactions. These multiples can be used as references and applied to the company's financial aggregates to deduce its valuation. The sample is selected by the analyst based on the characteristics of the company (size, growth, profitability, etc.). The analyst may also apply a premium/discount depending on his perception of the company's characteristics.
- 3. Assets and liabilities method: estimate of the value of equity capital based on revalued assets adjusted for the value of the debt.
- 4. Discounted dividend method: discounting of estimated future dividend flows. The discount rate used is generally the cost of capital.
- 5. Sum of the parts: this method consists of estimating the various activities of a company using the most appropriate valuation method for each of them, then realizing the sum of the parts.

Conflict of Interests between TP ICAP Midcap and the Issuer

G. Midcap and the Issuer have agreed to the provision by the former to the latter of a service for the production and distribution of the investment recommendation on the said Issuer: Star7

History of investment rating and target price - Star7





Distribution of Investment Ratings

Rating	Recommendation Universe*	Portion of these provided with investment
		banking services**
Buy	84%	64%
Hold	14%	38%
Sell	1%	50%
Under review	1%	o%

Midcap employs a rating system based on the following:

Buy: Expected to outperform the markets by 10% or more over a 6 to 12 months horizon.

Hold: expected performance between -10% and +10% compared to the market over a 6 to 12 months horizon.

Sell: Stock is expected underperform the markets by 10% or more over a 6 to 12 months horizon.

The history of ratings and target prices for the Issuers covered in this report are available on request at https://researchtpicap.midcapp.com/en/disclaimer.



General Disclaimer

This Report is confidential and is for the benefit and internal use of the selected recipients only. No part of it may be reproduced, distributed, or transmitted without the prior written consent of Midcap

This Report is published for information purposes only and does not constitute a solicitation or an offer to buy or sell any of the securities mentioned herein. The information contained in this Report has been obtained from sources believed to be reliable and public, Midcap makes no representation as to its accuracy or completeness. The reference prices used in this Report are closing prices of the day before the publication unless otherwise stated. All opinions expressed in this Report reflect our judgement at the date of the documents and are subject to change without notice. The securities discussed in this Report may not be suitable for all investors and are not intended to recommend specific securities, financial instruments, or strategies to particular clients. Investors should make their own investment decisions based on their financial situation and investment objectives. The value of the income from your investment may vary due to changes in interest rates, changes in the financial and operating conditions of companies and other factors. Investors should be aware that the market price of the securities discussed in this Report may be volatile. Due to the risk and volatility of the industry, the company, and the market in general, at the current price of the securities, our investment rating may not correspond to the stated price target. Additional information regarding the securities mentioned in this Report is available on request.

This Report is not intended for distribution or use by any entity who is a citizen or resident of, or an entity located in any locality, territory, state, country, or other jurisdiction where such distribution, publication, availability, or use would be contrary to or limited by law or regulation. Entity or entities in possession of this Report must inform themselves about and comply with any such restrictions, including MIFID II. This Report is only intended for persons who are Eligible Counterparties or Professional Clients within the meaning of MIFID II regulation. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. The Report is subject to restricted circulation. The research was conducted in accordance with the provisions of the Charter. Midcap has adopted effective administrative and organizational arrangements, including "information barriers", to prevent and avoid conflicts of interest regarding investment recommendations. The remuneration of financial analysts who participate in the preparation of the recommendation is not linked to the corporate finance activity.